FANCL’s Calolimit CVD and diabetes supplement backed by two new clinical trials
A FANCL-funded RCT study discovered that the ingestion of tea flower extract, mulberry leaf extract, and chitosan could reduce postprandial blood glucose and triglyceride levels in healthy subjects.
Two clinical trials have confirmed blood glucose and triglyceride levels were significantly lowered in the test group, compared to the placebo group.
FANCL will use these findings to market its Calolimit dietary supplement which is said to suppress sugar and fat absorption in healthy people.
The findings would be presented in June 2020, at The 20th Annual Meeting of the Japanese Society of Anti-Aging Medicine. The results were published in the medical journal, Japanese Pharmacology Therapeutics.
